MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company focused on marketing its advanced robotic-arm solution and its implants for minimally invasive orthopedic knee procedures known as MAKOplasty, today announced the commercial availability of the Lateral Unicompartmental Knee Resurfacing Application for its RIO Robotic Arm Interactive Orthopedic System. The new application complements MAKO’s existing unicompartmental and bicompartmental knee applications targeting the medial and patellofemoral compartments.

“We believe the advanced proprietary features of our RIO Robotic Arm System and the RESTORIS MCK bicompartmental knee implant system provide the potential to address a larger population of patients suffering from limited osteoarthritis in the knee,” said Dr. Maurice R. Ferre, President and CEO of MAKO. “Providing this lateral capability represents the achievement of another milestone towards the continuing commercialization of innovative technology that restores patient quality of life.”

Dr. Gary Poehling, a MAKOplasty surgeon at Wake Forest University Baptist Medical Center in Winston-Salem, NC, said, “The availability of the lateral knee application is another great advance in the MAKO product offering. I am now able to utilize MAKOplasty to treat patients with single compartment knee osteoarthritis, regardless if it is medial, lateral or patellofemoral.”

“MAKO has again taken a difficult, heavily instrumented procedure and made it much simpler to perform with accurate and reproducible results,” stated Dr. John Velyvis, a MAKOplasty surgeon at Eisenhower Medical Center in Rancho Mirage, CA. “The lateral application is a promising addition, especially in the minimally invasive treatment of women, who are more prone to this deformity.”

About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets both its RIO Robotic-Arm Interactive Orthopedic system and its proprietary RESTORIS implants for minimally invasive orthopedic knee procedures. The MAKO RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology and prepares the knee joint for the insertion and alignment of MAKO’s resurfacing RESTORIS implants through a minimal incision. The FDA-cleared RIO system allows surgeons to provide a precise, consistently reproducible tissue-sparing, bone resurfacing procedure called MAKOplasty to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. MAKO has an intellectual property portfolio of more than 250 licensed or owned patents and patent applications relating to the areas of robotics, haptics, computer assisted surgery and implants.

Additional information can be found at http://www.makosurgical.com.

“MAKOplasty,” “RESTORIS,” and “RIO,” as well as the “MAKO”
logo, whether standing alone or in connection with the words “MAKO Surgical Corp.” are trademarks of MAKO Surgical Corp.

Contacct-0-
Cynthia M. Kalb
MAKO Surgical Corp.
P:  954-927-2044 x426
E: